binimetinib
Sponsor PFE · listed as PFE
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
binimetinib is a clinical-stage drug asset sponsored by PFE, listed as PFE. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jun 2027 (month precision, medium confidence), tied to trial NCT05615818. The asset is in Phase 3 and currently recruiting, studied in Biliary Tract Neoplasms. It appears across 2 tracked trials in the CSA sample.
Next catalyst
Event typeREADOUT
Expected date2027-06-30
As disclosedJun 2027
Date precisionmonth
Confidencemedium
Trial & sponsor
Trial (NCT)NCT05615818
PhasePHASE3
StatusRECRUITING
Lead sponsorUNICANCER
Listed asPFE
Condition(s)Biliary Tract Neoplasms
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More PFE catalysts